WorldCat Identities

Wang, Chuanyue

Works: 6 works in 8 publications in 3 languages and 59 library holdings
Genres: Operas  Drama  Filmed performances  Handbooks and manuals 
Roles: Editor, Performer
Classifications: M1500.B7, 782.1
Publication Timeline
Most widely held works by Chuanyue Wang
Mefistofele by Arrigo Boito( Visual )

3 editions published in 2014 in Italian and held by 53 WorldCat member libraries worldwide

A forlorn, aged philosopher sets out on a perilous course when he makes a deal with the Devil in his monumental treatment of the Faust tale
Jing shen ke he li yong yao wen da( Book )

1 edition published in 2011 in Chinese and held by 2 WorldCat member libraries worldwide

Ben shu yi jing shen ke bu tong ji bing de he li yong yao wei zhang,Mei zhang cong zheng que xuan yong yao wu,He li ying yong yao wu,You xiao lian he yong yao,Bu liang fan ying fang zhi yi ji te bie zhu yi shi xiang deng ji ge fang mian,Yi yi wen yi da de xing shi lie chu gai ji bing yao wu zhi liao zhong ying dang te bie guan zhu de wen ti(zheng que zuo fa),Bing dui ci zuo chu jie da
Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Background: Antipsychotic drugs improve schizophrenia symptoms and reduce the frequency of relapse, but treatment response is highly variable. Little is known about the genetic factors associated with treatment response. We did a genome-wide association study of antipsychotic treatment response in patients with schizophrenia. Methods: The discovery cohort comprised patients with schizophrenia from 32 psychiatric hospitals in China that are part of the Chinese Antipsychotics Pharmacogenomics Consortium. Patients who met inclusion criteria were randomly assigned (1:1:1:1:1:1) to six groups (olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, and haloperidol or perphenazine; those assigned to haloperidol or perphenazine were subsequently assigned [1:1] to one or the other) for 6 weeks. Antipsychotic response was quantified with percentage change on the Positive and Negative Syndrome Scale. Single-nucleotide polymorphisms (SNPs) were tested for their association with treatment response. Linkage-disequilibrium-independent SNPs that exhibited potential associations (ie, p<1 × 10 −5 ) were tested in a validation cohort comprising patients from the Chinese Antipsychotics Pharmacogenetics Consortium from five collaborative hospitals, who were treated with olanzapine, risperidone, or aripiprazole for 8 weeks. Findings: The discovery cohort contained 2413 patients and the validation cohort 1379 patients. In the discovery cohort, we identified three novel SNPs (rs72790443 in MEGF10 [p=1·37 × 10 −8 ], rs1471786 in SLC1A1 [p=1·77 × 10 −8 ], and rs9291547 in PCDH7 [p=4·48 × 10 −8 ]) that were associated with antipsychotic treatment response at a genome-wide significance level. These associations were confirmed in the validation cohort (p<0·05). In the combined sample of the discovery and validation cohorts, we identified five novel loci showing genome-wide significant associations with general antipsychotic treatment response (rs72790443 in MEGF10 [p=1·40 × 10 −9 ], rs1471786 in SLC1A1 [p=2·33 × 10 −9 ], rs9291547 in PCDH7 [p=3·24 × 10 −9 ], rs12711680 in CNTNAP5 [p=2·12 × 10 −8 ], and rs6444970 in TNIK [p=4·85 × 10 −8 ]). In antipsychotic-specific groups, after the combination of results from both samples, the rs2239063 SNP in CACNA1C was associated with treatment response to olanzapine (p=1·10 × 10 −8 ), rs16921385 in SLC1A1 was associated with treatment response to risperidone (p=4·40 × 10 −8 ), and rs17022006 in CNTN4 was associated with treatment response to aripiprazole (p=2·58 × 10 −8 ). Interpretation: We have identified genes related to synaptic function, neurotransmitter receptors, and schizophrenia risk that are associated with response to antipsychotics. These findings improve understanding of the mechanisms underlying treatment responses, and the identified biomarkers could eventually guide choice of antipsychotic in patients with schizophrenia. Funding: National Key Technology R&D Program of China, National Natural Science Foundation of China
Symptomatic remission in schizophrenia: Results from a risperidone maintenance treatment study( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Abstract: This study aimed to investigate remission following the treatment of schizophrenia patients with risperidone. Clinically stabilized patients with schizophrenia (n = 374) were randomly assigned to 4-week, 26-week, or no-dose-reduction groups, in which the baseline risperidone dose was continued for 4, 26, or all weeks during 1-year period. The 'Positive and Negative Syndrome Scale' (PANNS) was assessed at baseline and monthly for six months, followed by every two months until the last recruited patient completed 1-year follow-up. Symptomatic remission was defined according to criteria established by the Schizophrenia Working Group. A Generalized Linear Mixed Model indicated significant variation in remission over time, which increased after baseline in the entire group (F = 49.32, df = 1, 3114, P <0.001). The overall length of risperidone treatment (F = 4.34, df = 1, 416, P = 0.038) and the duration of illness (F = 8.51, df = 1, 359, P = 0.004) had significantly negative effects upon remission. Baseline remission patients were associated with a significantly increased time to relapse compared with the baseline of non-remission patients over a one year follow up period (F = 5.74, df = 1, 367, P = 0.017). One-year risperidone maintenance treatment increased remission rates in schizophrenia. A shorter illness duration, risperidone treatment length, and a lower total PANSS score were clinically useful predictors of remission. Achieving remission may postpone relapse. Highlights: Increased remission rates via 1-year maintenance treatment in schizophrenia. A shorter duration of illness was factor able to successfully predict remission. The achievement of remission may postpone relapse
Impact of childhood trauma on sensorimotor gating in Chinese patients with chronic schizophrenia( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Abstract: We investigated the relationship between childhood trauma (CT) and sensorimotor gating in Chinese patients diagnosed with chronic schizophrenia. Seventy-five patients were assessed with the Childhood Trauma Questionnaire-Short Form (CTQ-SF), and then the modified paradigm, perceived spatial separation-induced prepulse inhibition (PSS PPI) and the perceived spatial co-location PPI (PSC PPI or classical PPI) were applied to test sensorimotor gating. Startling stimuli (90dB) were presented either alone or preceded by discrete prepulse stimuli of 4dB in a background 60-dB noise level. Associations between CT and various PPI paradigms were statistically analyzed. Univariate analysis revealed the absence of a significant correlation between CT and PPI paradigms (p> 0.05). However, multiple linear regression analyses revealed that sexual abuse and the positive and negative syndrome scale (PANSS) score were negatively correlated with PSS PPI (p = 0.029 and 0.008, respectively). On the other hand, female sex and history of smoking were positively correlated with PSS PPI (p = 0.044 and 0.043, respectively). In conclusion, the results of this study suggest that CT can be a predisposing factor that affects sensorimotor gating in schizophrenia patients. Highlights: This was among the first studies to examine childhood trauma on sensory gating in patients with schizophrenia. We used the modified paradigm, perceived spatial separation-induced PPI (PSS PPI) to test the sensory gating. Our results suggest that childhood trauma can be a predisposing factor that affects sensory gating in schizophrenia patients
L'opera dai grandi teatri del mondo by Arrigo Boito( Visual )

1 edition published in 2016 in Italian and held by 1 WorldCat member library worldwide

Audience Level
Audience Level
  Kids General Special  
Audience level: 0.57 (from 0.53 for Mefistofel ... to 0.99 for L'opera da ...)